Literature DB >> 8879993

Molecular genetic basis of the human chondrodysplasias.

W A Horton1.   

Abstract

Considerable progress has been made in delineating the molecular genetic basis of the human chondrodysplasias. Two genes emerge as harboring mutations found in patients with the most common disorders. Mutations in the type II collagen gene account for most spondyloepiphyseal dysplasia and spondyloepiphyseal dysplasia-like clinical disorders, whereas mutations in the fibroblast growth factor receptor 3 gene are responsible for achondroplasia, thanatophoric dysplasia, and hypochondroplasia. A substantial portion of remaining patients have mutations of the genes encoding cartilage oligomeric matrix protein or diastrophic dysplasia sulfate transporter.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8879993     DOI: 10.1016/s0889-8529(05)70347-9

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  4 in total

1.  Autosomal recessive disorder otospondylomegaepiphyseal dysplasia is associated with loss-of-function mutations in the COL11A2 gene.

Authors:  M Melkoniemi; H G Brunner; S Manouvrier; R Hennekam; A Superti-Furga; H Kääriäinen; R M Pauli; T van Essen; M L Warman; J Bonaventure; P Miny; L Ala-Kokko
Journal:  Am J Hum Genet       Date:  2000-02       Impact factor: 11.025

2.  Prevalence of Mutations in the FGFR3 Gene in Individuals with Idiopathic Short Stature.

Authors:  Mitsukazu Mamada; Tohru Yorifuji; Keiji Kurokawa; Masahiko Kawai; Toru Momoi; Tatsutoshi Nakahata
Journal:  Clin Pediatr Endocrinol       Date:  2006-04-29

Review 3.  A Track Record on SHOX: From Basic Research to Complex Models and Therapy.

Authors:  Antonio Marchini; Tsutomu Ogata; Gudrun A Rappold
Journal:  Endocr Rev       Date:  2016-06-29       Impact factor: 19.871

4.  Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes.

Authors:  S U Lauvrak; E Munthe; S H Kresse; E W Stratford; H M Namløs; L A Meza-Zepeda; O Myklebost
Journal:  Br J Cancer       Date:  2013-09-24       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.